Hemispherx BioPharma, Inc. (HEB) financial statements (2021 and earlier)

Company profile

Business Address 2117 SW HIGHWAY 484
OCALA, FL 32801
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments391026916
Cash and cash equivalents39101222
Short-term investments   13714
Receivables1110   
Prepaid expense      0
Assets held-for-sale, not part of disposal group   11 
Other undisclosed current assets182102 
Total current assets:40104471117
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment678910115
Intangible assets, net (including goodwill)1111111
Intangible assets, net (excluding goodwill)1111111
Other noncurrent assets1111200
Other undisclosed noncurrent assets15     7
Total noncurrent assets:24101011121213
TOTAL ASSETS:65201414192329
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1123224
Accounts payable0011112
Accrued liabilities0012212
Debt00   00
Other undisclosed current liabilities0 4    
Total current liabilities:1153224
Noncurrent Liabilities
Long-term debt and lease obligation2222   
Long-term debt, excluding current maturities2222   
Operating lease, liability00
Total noncurrent liabilities:2222   
Total liabilities:3385224
Stockholders' equity
Stockholders' equity attributable to parent, including:611359152025
Preferred stock1      
Common stock0000000
Additional paid in capital403340324317316313303
Accumulated other comprehensive income (loss)(0) (0)0(0)(0)(0)
Accumulated deficit(342)(328)(319)(309)(301)(293)(278)
Other undisclosed stockholders' equity attributable to parent 1     
Total stockholders' equity:611359152025
Other undisclosed liabilities and equity04111  
TOTAL LIABILITIES AND EQUITY:65201414192329

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues0000000
Revenue, net0000
Cost of revenue(1)(2)(2)(1)(1)(2)(1)
Cost of goods and services sold(1)(1)(1)(1)(1)(2) 
Gross profit:(1)(2)(1)(1)(1)(1)(1)
Operating expenses(14)(11)(10)(11)(13)(15)(18)
Operating loss:(15)(12)(11)(11)(14)(17)(19)
Interest and debt expense(1)(0)(1)(0) (0)(0)
Loss before gain (loss) on sale of properties:(16)(13)(12)(12)(14)(17)(19)
Other undisclosed net income      2
Net loss:(16)(13)(12)(12)(14)(17)(17)
Other undisclosed net income attributable to parent132361 
Net loss available to common stockholders, diluted:(14)(10)(10)(8)(8)(15)(17)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(16)(13)(12)(12)(14)(17)(17)
Other comprehensive loss      (17)
Other undisclosed comprehensive income      17
Comprehensive loss:(16)(13)(12)(12)(14)(17)(17)
Other undisclosed comprehensive income, net of tax, attributable to parent132361 
Comprehensive loss, net of tax, attributable to parent:(14)(10)(10)(8)(7)(15)(17)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: